COGNITION THERAPEUTICS INC
CGTXDrugs in Pipeline
6
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
This month
Market Overview
Stock performance and key metrics
2 upcoming, 1 past
golexanolone Phase 2 Est. Readout
Primary completion for golexanolone trial (NCT07304843) in Primary Biliary Cholangitis (PBC)
Source1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How CGTX's past catalysts played out
CBD 100 mg/mL Oral Solution
Psychosis
CT1812
Early Alzheimer's Disease
C105
Cognition Disorders
golexanolone
Primary Biliary Cholangitis (PBC)
Active Treatment- CT1812 100 mg
Alzheimer Disease
Dexmedetomidine
Alzheimer Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CBD 100 mg/mL Oral Solution | Phase 3 | Psychosis | - | - |
CT1812 | Phase 2 | Early Alzheimer's Disease | - | - |
C105 | Phase 2 | Cognition Disorders | - | - |
golexanolone | Phase 2 | Primary Biliary Cholangitis (PBC) | - | - |
Active Treatment- CT1812 100 mg | Phase 2 | Alzheimer Disease | - | - |
Dexmedetomidine | Phase 2 | Alzheimer Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in COGNITION THERAPEUTICS INC's drug pipeline?→
CatalystAlert tracks 6 drug candidates in COGNITION THERAPEUTICS INC's (CGTX) pipeline across Phase 3, Phase 2. Its lead program is CBD 100 mg/mL Oral Solution (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is COGNITION THERAPEUTICS INC's next FDA catalyst?→
COGNITION THERAPEUTICS INC's (CGTX) next tracked catalyst is a Conference expected September 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CGTX biotech catalysts?→
Add CGTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow COGNITION THERAPEUTICS INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.